Altos Therapeutics, LLC

Novartis Ag

Vicuron Pharmaceuticals Inc.

Vicuron Holdings LLC

Millennium Pharmaceuticals Limited

Arathi Sundaram

Pascal Jean Druzgala

Rakesh K Jain

Gary W Luehr

Mohindra Seepersaud

Lei Shu

Zhengyu Yuan

Charles Francavilla

Priyadarshini Jaishankar

Philip W Payne

Simon Bushell

Kathryn Rene Bracken

Karl Dean

Kwangho Lee

Provided are Dor Dantagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R, Rand Rare as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine Dor Dreceptor from the compounds of the invention.

[object Object]

Novel N-formyl hydroxylamine compounds of formula I: wherein

N-formyl hydroxylamines compounds

Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed.

N-formyl hydroxylamines

Growing community of inventors

Fremont, CA, United States of America

Arathi Sundaram